Table 1

Glossary and definitions (after76)

Term	Definition
Poor prognostic factors	Persistently moderate or high disease activity (after csDMARD therapy) according to composite measures including joint counts despite csDMARD therapy High acute phase reactant levels High swollen joint count Presence of RF and/or ACPA, especially at high levels Presence of early erosions Failure of 2 or more csDMARDs
Low dose glucocorticoids	<7.5 mg/day prednisone equivalent
Short-term	Up to 3 months
Tapering	Reduction of drug dose or increase of the interval between doses May include cessation (tapering to 0), but then only after slow reduction
Discontinuation, cessation, stopping	Stopping of a particular drug
Disease activity states
Remission	ACR-EULAR remission definition (Boolean or index-based); sustained remission: ACR-EULAR-defined remission for ≥6 months
Low disease activity	Low disease activity state according to validated composite disease activity measures that include joint counts, performed by a HCP; sustained low disease activity: low disease activity for ≥6 months
Moderate, high disease activity	Respective disease activity state according to validated composite disease activity measures that include joint counts by a HCP
DMARD nomenclature
Synthetic DMARDs	Conventional synthetic DMARDs	For example, methotrexate, leflunomide, sulfasalazine, hydroxychloroquine
Synthetic DMARDs	Targeted synthetic DMARDs	For example, baricitinib, filgotinib, tofacitinib, upadacitinib
Biological DMARDs	Biological originator DMARDs	TNFi: adalimumab, certolizumab, etanercept, golimumab, infliximab; IL-6Ri: sarilumab, tocilizumab; Co-stimulation-i: abatacept; anti-B-cell (CD20): rituximab
Biological DMARDs	Biosimilar DMARDs	Currently for adalimumab, etanercept, infliximab, rituximab

ACPA, anti-citrullinated protein antibody; ACR, American College of Rheumatology; csDMARDs, conventional synthetic disease-modifying antirheumatic drugs; HCP, healthcare professional; RF, rheumatoid factor.